Rosângela Caetano1, Cláudia Regina Garcia Bastos1,2, Ione Ayala Gualandi de Oliveira1,3, Rondineli Mendes da Silva1,4, Clarisse Pereira Dias Drumond Fortes1, Vera Lucia Edais Pepe4, Lenice Gnocchi Reis4, José Ueleres Braga1,4. 1. Institute of Social Medicine, State University of Rio de Janeiro (Universidade do Estado do Rio de Janeiro - UERJ), Rio de Janeiro, Brazil. 2. Regional Council of Pharmacy of the State of Rio de Janeiro (Conselho Regional de Farmácia do Estado do Rio de Janeiro - CRF-RJ), Rio de Janeiro, Brazil. 3. Severino Sombra University (Universidade Severino Sombra), Rio de Janeiro, Brazil. 4. Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation (Escola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz), Rio de Janeiro, Brazil.
Abstract
BACKGROUND: The purpose of this review was to present a meta-analysis aimed to evaluate the accuracy of positron emission tomography (PET) and PET-CT for detecting recurrence of differentiated thyroid carcinoma (DTC) not identified by (131) I whole-body scintigraphy. METHODS: MEDLINE, EMBASE, LILACS, and Cochrane databases were searched for studies published between January 1985 and March 2012. Systematic methods were used to select and evaluate the quality of studies. Pooled sensitivity and specificity for conventional PET and PET-CT was estimated using random effects model. RESULTS: Twenty studies were included in the systematic review; the data of 18 studies were used in the meta-analysis. The combined sensitivity and specificity for conventional PET were both found to be 84%; for PET-CT, they were 93% and 81%, respectively. The overall accuracies were 91% and 93%, respectively. CONCLUSION: (18) Fluorodeoxyglucose (FDG)-PET and PET-CT are highly accurate diagnostics tools for DTC recurrence in patients who present a negative whole-body scintigraphy and could impact the clinical and therapeutic management of DTC.
BACKGROUND: The purpose of this review was to present a meta-analysis aimed to evaluate the accuracy of positron emission tomography (PET) and PET-CT for detecting recurrence of differentiated thyroid carcinoma (DTC) not identified by (131) I whole-body scintigraphy. METHODS: MEDLINE, EMBASE, LILACS, and Cochrane databases were searched for studies published between January 1985 and March 2012. Systematic methods were used to select and evaluate the quality of studies. Pooled sensitivity and specificity for conventional PET and PET-CT was estimated using random effects model. RESULTS: Twenty studies were included in the systematic review; the data of 18 studies were used in the meta-analysis. The combined sensitivity and specificity for conventional PET were both found to be 84%; for PET-CT, they were 93% and 81%, respectively. The overall accuracies were 91% and 93%, respectively. CONCLUSION: (18) Fluorodeoxyglucose (FDG)-PET and PET-CT are highly accurate diagnostics tools for DTC recurrence in patients who present a negative whole-body scintigraphy and could impact the clinical and therapeutic management of DTC.
Authors: Jaime L Wiebel; Nazanene H Esfandiari; Maria Papaleontiou; Francis P Worden; Megan R Haymart Journal: Thyroid Date: 2015-08-03 Impact factor: 6.568
Authors: Johann-Martin Hempel; Roman Kloeckner; Sandra Krick; Daniel Pinto Dos Santos; Simin Schadmand-Fischer; Patrick Boeßert; Sotirios Bisdas; Matthias M Weber; Christian Fottner; Thomas J Musholt; Mathias Schreckenberger; Matthias Miederer Journal: Cancer Imaging Date: 2016-11-03 Impact factor: 3.909
Authors: Le Ngoc Ha; Amir Iravani; Nguyen Thi Nhung; Ngo Thi Minh Hanh; Febby Hutomo; Mai Hong Son Journal: Cancer Imaging Date: 2021-01-07 Impact factor: 3.909